TY - JOUR
T1 - High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia
AU - Mabuchi, Ryoko
AU - Hara, Takeshi
AU - Matsumoto, Takuro
AU - Shibata, Yuhei
AU - Nakamura, Nobuhiko
AU - Nakamura, Hiroshi
AU - Kitagawa, Junichi
AU - Kanemura, Nobuhiro
AU - Goto, Naoe
AU - Shimizu, Masahito
AU - Ito, Hiroyasu
AU - Yamamoto, Yasuko
AU - Saito, Kuniaki
AU - Moriwaki, Hisataka
AU - Tsurumi, Hisashi
N1 - Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2016/1/2
Y1 - 2016/1/2
N2 - The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 M (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.
AB - The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 M (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.
UR - http://www.scopus.com/inward/record.url?scp=84954287348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954287348&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1041388
DO - 10.3109/10428194.2015.1041388
M3 - Article
C2 - 25907424
AN - SCOPUS:84954287348
SN - 1042-8194
VL - 57
SP - 92
EP - 98
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -
